Crossmark

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Crossref DOI link: https://doi.org/10.1007/s00296-021-05016-w

Published Online: 2021-10-08

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miler, Marijana https://orcid.org/0000-0002-0569-924X
Nikolac Gabaj, Nora https://orcid.org/0000-0001-6831-6309
Ćelap, Ivana https://orcid.org/0000-0002-3982-5777
Grazio, Simeon https://orcid.org/0000-0003-3407-0317
Tomašić, Vedran https://orcid.org/0000-0001-8211-3487
Bišćanin, Alen https://orcid.org/0000-0003-2923-4110
Mitrović, Joško https://orcid.org/0000-0001-9190-7828
Đerek, Lovorka https://orcid.org/0000-0002-3041-7718
Morović-Vergles, Jadranka https://orcid.org/0000-0002-2672-8871
Vrkić, Nada https://orcid.org/0000-0001-5190-5393
Štefanović, Mario https://orcid.org/0000-0002-3965-3231
License Information

Text and Data Mining valid from 2021-10-08

Version of Record valid from 2021-10-08
More Information

Article History

Received: 13 July 2021

Accepted: 27 September 2021

First Online: 8 October 2021

Declarations

:

: There are no conflicts of interest to disclose.The study was designed in accordance with the Declaration of Helsinki and approved by the Ethical Committees of the Sestre milosrdnice University Hospital Center, Faculty of Pharmacy and University Hospital Dubrava, Zagreb.

Document is current

Any future updates will be listed below